The San Antonio Breast Cancer Symposium®, now in its 42nd year, is the premier conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world. More than 7,500 health care professionals from more than 90 countries are expected to attend.
The Best of SABCS® official highlights programs allow professionals, who are unable to travel to San Antonio, the opportunity to experience and discuss the most current research and advances in the field of breast cancer with colleagues and key opinion leaders.
New York City, New York
February 8th, 2020
In collaboration with ESHOS
These regional symposia are directed to academic and community physicians, medical residents and fellows training in oncology subspecialties, physician assistants, nurse practitioners and basic/translational researchers involved in breast cancer. Specialties include medical, surgical, gynecologic, and radiation oncology, as well as other pertinent healthcare professionals involved in breast cancer medicine.
The Long School of Medicine designates this live activity up to a maximum of 3.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Identify factors that predispose individuals and increase the risk of developing breast cancer.
• Describe prognostic and predictive molecular signatures and biomarkers that can identify the most appropriate treatment strategies for individuals with breast cancer.
• Discuss scientific advances from the laboratory that have great potential to translate into increased knowledge of breast cancer biology and pathogenesis.
• Review new results from clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium® .
• Discuss on results of evidence from preclinical research and clinical trials that support the rational combinations of traditional and newer pharmacologic interventions, with a focus on novel therapeutics and resistance mechanisms.
• Develop appropriate individualized treatment strategies for those patients who would benefit from new treatments in all the major subtypes of breast cancer and also focus on reversing resistance to commonly used therapies.
Education to improve physician understanding of the latest trial data, guidelines, and applications in clinical practice has been identified as a vehicle for closing the knowledge gap and helping to improve patient outcomes [Christian 2006]. This proposed CME symposium will address the above gaps in clinical practice/knowledge between what is known and what healthcare practitioners wish to better understand regarding the screening, diagnosis, and management of patient with BC. In addition, it will focus on identified research/presentations from SABCS® 2019 that cover these issues, including results of BC research, facilitating the rapid translation of new knowledge into better care for breast cancer patients and addressing issues such as axillary management in primary BC, human epidermal growth factor receptor 2 (HER2), cell cycle regulation with CDK inhibitors, genomic heterogeneity, and proteomic analysis of BC.
|Contact No. :||+1 443-370-2698|
|Registration Type||End Date||Price|
|Early Fee||06 Feb,2020||USD 75.00|
|On-Site Fee||08 Feb,2020||USD 90.00|
|ESHOS Member Fee||07 Feb,2020||USD 25.00|
|Fellow, Resident, Nurse Practitioner Fee||07 Feb,2020||USD 25.00|
|Industry Attendees Early Fee||06 Feb,2020||USD 100.00|
|Industry Attendees On-Site Fee||08 Feb,2020||USD 125.00|
Plan Your Travel
Reviews Given by People
Hotels Near Venue
Subscribe to our Newsletterx
Subscribe to our newsletter and receive updates on medical conferences, board review courses and news